NCT03367546 is a Phase 2 clinical trial of Blood and Marrow Transplant in Sickle Cell Disease, sponsored by Masonic Cancer Center, University of Minnesota.

Who is sponsoring NCT03367546?

NCT03367546 is sponsored by Masonic Cancer Center, University of Minnesota.

What drugs are being tested in NCT03367546?

Interventions in NCT03367546: Blood and Marrow Transplant.

What condition does NCT03367546 study?

NCT03367546 studies Sickle Cell Disease, Thalassemia, High Risk Hematologic Disorders, Cerebral Adrenoleukodystrophy, Inherited Metabolic Disorders.

Is NCT03367546 still recruiting?

NCT03367546 is currently terminated. Last updated 12 July 2024.

Last reviewed 2024-07-12 · How we verify

NCT03367546

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases

Terminated Phase 2 Last updated 12 July 2024

What this trial tests

Phase 2 trial testing Blood and Marrow Transplant in Sickle Cell Disease in 5 participants. Terminated before completion.

Timeline

2 July 2018

Primary endpoint
19 December 2022

19 December 2022

Quick facts

Lead sponsor	Masonic Cancer Center, University of Minnesota
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	5
Start date	2 July 2018
Primary completion	19 December 2022
Estimated completion	19 December 2022
Sites	1 location across United States

Drugs / interventions tested

Blood and Marrow Transplant

Conditions studied

Sickle Cell Disease — all drugs for Sickle Cell Disease →
Thalassemia — all drugs for Thalassemia →
High Risk Hematologic Disorders — all drugs for High Risk Hematologic Disorders →
Cerebral Adrenoleukodystrophy — all drugs for Cerebral Adrenoleukodystrophy →

Sponsor

Masonic Cancer Center, University of Minnesota

Who can join

Adults 0 to 25, any sex, with Sickle Cell Disease or Thalassemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase II study for the use of T-cell replete reduced intensity conditioning (RIC) haploidentical donor allogeneic hematopoietic cell transplantation (HaploHCT) for individuals with high-risk non-malignant diseases who lack a suitable HLA-matched sibling donor.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Adoptive T Cell Therapy Following Haploidentical Hematopoietic Stem Cell Transplantation.
Zhang P, Tey SK. · · 2019 · cited 11× · PMID 31447852 · DOI 10.3389/fimmu.2019.01854
Allogeneic Transplant and Gene Therapy: Evolving Toward a Cure.
Lawal RA, Walters MC, Fitzhugh CD. · · 2022 · cited 4× · PMID 36400545 · DOI 10.1016/j.hoc.2022.06.007
Stem cell therapies in the clinic.
Acharya S, Shaha S, Bibbey MG, Mukherji M, et al · · 2025 · cited 3× · PMID 40385529 · DOI 10.1002/btm2.70000

Verify or expand the search:

Other recruiting trials for Sickle Cell Disease

Currently open trials in the same condition.

NCT07369024 — Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults · Phase 2 · recruiting
NCT06016634 — Alendronate for Osteonecrosis in Adults With Sickle Cell Disease · Phase 2 · recruiting
NCT06260891 — Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial · Phase 2 · recruiting
NCT07222475 — Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease · NA · recruiting
NCT07224360 — Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) · Phase 2 · recruiting

Other Masonic Cancer Center, University of Minnesota trials

Trials by the same sponsor.

NCT06772090 — Probiotic Supplementation During Cytotoxic Chemotherapy for Solid Tumor Malignancies · NA · not yet recruiting
NCT06584929 — Rural Smoking Cessation · NA · not yet recruiting
NCT07153016 — LEgal Guidance and AdvocaCY for CAREgivers (LEGACY CARE): A Pilot Clinical Trial for Caregivers of Persons With Colorect · NA · recruiting
NCT06792825 — HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL · Phase 2 · recruiting
NCT07070726 — UNTOLD Ovarian Cancer Unmet Needs Survey · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03367546 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Masonic Cancer Center, University of Minnesota
Last refreshed: 12 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03367546.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing